Phase II randomized study of pembrolizumab with or without epigenetic modulation with CC-486 in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
|Effective start/end date||12/1/16 → 6/30/22|
- TRANSLATIONAL RESEARCH IN ONCOLOGY
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.